Home
Drugs
Trastuzumab
Clinical Trials

Clinical Trials Related to Trastuzumab

Related studies linked through entity extraction aliases.

A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Status: UNKNOWN
Phase: PHASE2

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Status: UNKNOWN
Phase: N/A

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Status: RECRUITING
Phase: PHASE2

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Status: UNKNOWN
Phase: PHASE2

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Status: COMPLETED
Phase: PHASE3

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Status: UNKNOWN
Phase: N/A

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

CRAFT: The NCT-PMO-1602 Phase II Trial

Status: COMPLETED
Phase: PHASE2

TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

Status: WITHDRAWN
Phase: PHASE1/PHASE2

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

Status: TERMINATED
Phase: PHASE2

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Status: COMPLETED
Phase: PHASE2/PHASE3

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

MARGetuximab Or Trastuzumab (MARGOT)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Status: WITHDRAWN
Phase: PHASE2

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2